Serina Therapeutics, Inc. Form 4 Filing by Chief Scientific Officer Randall Moreadith

On August 4, 2025, Randall Moreadith, the Chief Scientific Officer of Serina Therapeutics, Inc., filed a Form 4 with the SEC detailing transactions involving the company's common stock and stock options. Moreadith acquired 5,500 shares of common stock at a price of $0.06 per share and subsequently sold the same number of shares at a weighted average price of $5.17 per share. Additionally, he exercised stock options to acquire 5,500 shares of common stock, which are fully vested and expire on May 6, 2031. Following these transactions, Moreadith owns 478,990 shares of common stock. The transactions were reported under the codes 'M' for acquisition and 'S' for sale, with no equity swaps involved.